Genomind vs. GeneSight: Which Pharmacogenomic Test Is Better for Psychiatric Medication?

Medically reviewed by Dr. Maria Carmen V. Gonzales-Vigilar, MD, MS - Last updated May 2026

If you have ever started an antidepressant or ADHD medication and felt let down by the results, you are not alone. Many patients try several medications before finding one that genuinely helps. Pharmacogenomic testing is one tool that can shorten that cycle.

Two names dominate the pharmacogenomic conversation in psychiatry: Genomind and GeneSight. Patients at our Ashburn, VA practice often ask which one is better. Both are reputable tests built on the same science. They differ in the genes they cover, the way they report results, and how they fit a clinician's workflow.

Why Your DNA Matters for Psychiatric Medication

What Is Pharmacogenomics? A Plain Language Explanation

Pharmacogenomics is the study of how your genes affect the way your body processes medication. The word comes from pharmaco (drugs) and genomics (the study of genes). For a deeper scientific overview, the NIMH information on pharmacogenomics is a useful starting point.

Every person inherits a unique set of genetic instructions for the enzymes that break medications down in the liver and for the receptors those medications act on in the brain. Two people taking the same dose of the same antidepressant can have very different blood levels and very different responses.

A pharmacogenomic test reads a small panel of these relevant genes from a cheek swab and produces a report that flags which medications are likely to be processed normally, too quickly, too slowly, or to interact poorly with the receptors they target.

Why Some Antidepressants Work for Some People and Not Others

The most studied genes in psychiatric pharmacogenomics are members of the cytochrome P450 (CYP450) family, particularly CYP2D6 and CYP2C19. These liver enzymes metabolize many SSRIs, SNRIs, tricyclics, antipsychotics, and benzodiazepines.

Patients are typically classified as poor, intermediate, normal, rapid, or ultra-rapid metabolizers. A poor metabolizer may build up unusually high blood levels on a standard dose, leading to side effects. An ultra-rapid metabolizer may clear the medication so quickly that the drug feels like it is not working.

Other genes on these panels include SLC6A4 (the serotonin transporter), HTR2A (a serotonin receptor), MTHFR (folate metabolism), and COMT (dopamine breakdown). Variants in these genes can also affect whether a given medication is the right fit.

How Genetic Testing Helps Psychiatrists Prescribe More Accurately

Pharmacogenomic results do not replace clinical judgment. They add one more data layer alongside your symptoms, history, prior medication trials, and lab work. With a report in hand, a psychiatrist can:

• Avoid medications you are likely to metabolize poorly.
• Start at a more informed dose for medications that do fit.
• Anticipate drug-drug interactions before they happen.
• Reduce the trial-and-error cycle that frustrates so many patients with treatment-resistant depression.

What Is GeneSight?

Who Makes GeneSight and How It Works

GeneSight is made by Myriad Genetics, a molecular diagnostics company headquartered in Salt Lake City. The GeneSight Psychotropic test has been on the market since 2009 and is one of the most widely ordered pharmacogenomic tests in psychiatry.

The test is performed on a buccal (cheek) swab. The sample is sent to the Myriad lab, the relevant genes are sequenced, and a report is generated, typically within three to five business days.

What Genes GeneSight Tests

GeneSight Psychotropic analyzes pharmacokinetic genes (CYP2D6, CYP2C19, CYP2C9, CYP3A4, CYP1A2, UGT2B15) and pharmacodynamic genes (SLC6A4, HTR2A). Myriad uses an internal algorithm that combines results across these genes to score each medication.

How GeneSight Results Are Reported

GeneSight reports group medications into three columns: Use as Directed, Moderate Gene-Drug Interaction, and Significant Gene-Drug Interaction. Each medication is flagged with footnotes about the specific genetic finding driving the categorization. Coverage spans more than 60 FDA-approved psychiatric medications, including antidepressants, anti-anxiety medications, mood stabilizers, antipsychotics, and ADHD treatments.

What Is Genomind?

Who Makes Genomind and How It Works

Genomind is produced by Genomind, Inc., a precision medicine company in King of Prussia, Pennsylvania. The flagship product is the Genomind Professional PGx test, which has been refined through several iterations since 2010. For clinical detail, see Genomind Professional PGx clinical information.

Like GeneSight, Genomind uses a buccal swab. The sample is processed in Genomind's CLIA-certified lab, and a clinician-facing report is delivered through a secure portal in three to five business days.

What Genes Genomind Tests

The Genomind Professional PGx panel evaluates roughly 24 genes and covers more than 130 medications across psychiatry, neurology, cardiovascular care, and pain management. The genes include major CYP450 enzymes (CYP2D6, CYP2C19, CYP2C9, CYP3A4, CYP1A2, CYP2B6), pharmacodynamic genes (SLC6A4, HTR2A, HTR2C, ADRA2A, DRD2, COMT, OPRM1), and additional markers (MTHFR, ANK3, CACNA1C, BDNF, GRIK4) studied for their role in mood, anxiety, and treatment response.

How Genomind Results Are Reported

Genomind reports use a clean, color-coded medication list. Each medication is sorted into one of three categories:

• Green - Use as Directed: No relevant gene-drug interaction identified.
• Yellow - Moderate Gene-Drug Interaction: Use with caution; dosing adjustments or closer monitoring may be appropriate.
• Red - Significant Gene-Drug Interaction: Consider an alternative medication or significant dose adjustment.

Each medication entry links out to the specific genetic finding behind the score, plus dosing guidance from CPIC (the Clinical Pharmacogenetics Implementation Consortium) where available. The clinician portal also flags drug-drug interactions when the patient's full medication list is entered.

Head to Head: Genomind vs. GeneSight at a Glance

Both tests are FDA-registered laboratory developed tests run in CLIA-certified labs. The differences come down to breadth of panel, report design, and how each one fits a given practice.

Feature	Genomind Professional PGx	GeneSight Psychotropic
Manufacturer	Genomind, Inc. (King of Prussia, PA)	Myriad Genetics (Salt Lake City, UT)
Genes tested	Approximately 24 genes	Approximately 14 genes
Medications covered	130+ across psychiatry, neurology, pain, cardiology	60+ primarily psychiatric medications
Report format	Color-coded green / yellow / red, with CPIC guidance	Three columns: Use as Directed, Moderate, Significant Interaction
Sample type	Buccal (cheek) swab	Buccal (cheek) swab
Turnaround time	3 to 5 business days	3 to 5 business days
Insurance coverage	Often partially covered; varies by plan and indication	Often partially covered; Medicare reimbursement available in some cases
Patient out-of-pocket maximum	Capped patient pay program available	Patient assistance program available
Clinical decision support tools	Drug-drug interaction checker, condition-specific guidance	Built-in flags within report; clinician phone consultation

Both companies cite peer-reviewed studies supporting clinical utility, and independent meta-analyses have found modest but measurable improvements in remission rates with pharmacogenomic-guided prescribing, particularly for depression patients who have already failed at least one medication trial.

What the Results Actually Tell Your Psychiatrist

Green, Yellow, and Red Categories Explained

The color or column system is a shorthand, not a verdict. Green ("Use as Directed") means no known significant gene-drug interaction; it does not guarantee the medication will work, since effectiveness still depends on diagnosis, dose, and adherence.

Yellow ("Moderate") means a gene variant may change how you metabolize or respond to that medication. Your psychiatrist may still prescribe it, often at a different starting dose or with closer monitoring. Red ("Significant") means a meaningful gene-drug concern, such as poor metabolism that could lead to side effects or ultra-rapid metabolism that could undercut effectiveness.

How the Results Inform Prescribing Decisions

For a medication-naive patient, results help narrow the field to first-line options most likely to be tolerated. For a patient who has already tried several medications without success, the report often explains why previous trials failed and points toward alternatives. The report also informs dosing: a poor CYP2D6 metabolizer may need a lower starting dose, while a rapid metabolizer may need a higher dose or a different drug entirely.

What Genetic Testing Cannot Tell You

Honest expectations are essential. Pharmacogenomic testing does not tell you:

• Which exact medication will make you feel better.
• Whether you have depression, anxiety, ADHD, or any other condition (diagnosis still requires clinical evaluation).
• How long you should stay on a medication.
• Whether you will experience every potential side effect.
• Outcomes for medications or supplements not on the panel.

Pharmacogenomic data is one input. It works best alongside a thorough psychiatric evaluation and ongoing clinical follow-up.

Is Pharmacogenomic Testing Covered by Insurance?

Coverage varies. Both Genomind and GeneSight bill insurance directly and frequently obtain partial or full coverage when there is medical necessity, such as a major depression diagnosis with at least one failed medication trial. Medicare covers pharmacogenomic testing in some scenarios, and many commercial payers follow similar policies.

Both companies offer patient assistance or capped out-of-pocket pricing for those without full coverage. Genomind's patient pay program sets a maximum dollar amount the patient will be charged regardless of insurance. We encourage every patient to verify benefits before testing.

How Genomind Is Used at Gonzales-Vigilar Psychiatric Services

Our practice has chosen Genomind as our pharmacogenomic test. Three factors drove the decision:

• Broader gene panel. The 24-gene panel covers pharmacodynamic markers (MTHFR, COMT, BDNF, ANK3) that influence mood and treatment response, not only drug metabolism.
• Wider medication coverage. 130+ medications across multiple specialties means the same report stays useful as care evolves and as we coordinate with primary care or neurology.
• Clinician decision support. The Genomind portal integrates drug-drug interaction checks and CPIC-aligned dosing guidance, which streamlines our medication management workflow.

This is not a criticism of GeneSight, which remains an excellent test that many psychiatrists rely on. Genomind simply best matches our case mix and workflow.

How the Swab Is Taken

Collection takes about two minutes. After your psychiatric evaluation or follow-up, our team provides a Genomind kit and gently swabs the inside of your cheek for roughly thirty seconds. The sample is sealed and shipped to Genomind's lab the same day.

How Results Are Discussed at Your Follow-Up Appointment

Results are typically available within three to five business days. We schedule a dedicated follow-up visit to review the report together, walk through the green, yellow, and red categories, explain the genetic findings most relevant to you, and discuss how the data will (or will not) change your prescription plan. You leave with a printed copy that is yours to keep and share with future providers.

Who Benefits Most From Pharmacogenomic Testing?

Pharmacogenomic testing is not necessary for every patient, but it can be especially valuable for:

• Patients with treatment-resistant depression who have failed two or more medication trials.
• Patients who experience unusually severe or unexpected side effects on standard doses.
• Patients on multiple medications where drug-drug interactions are a concern.
• Patients with a family history of poor medication response.
• Patients who want a data-driven starting point before beginning a long-term psychiatric medication.

For straightforward first-line cases, evidence-based prescribing with careful follow-up still works well. Pharmacogenomics is an additional tool, not a default.

Frequently Asked Questions

Is Genomind covered by insurance?

Genomind is often partially or fully covered when there is medical necessity, such as a major depressive disorder diagnosis with at least one prior failed medication trial. Coverage varies by plan, indication, and medical history. Our team will help you verify your benefits before testing, and Genomind also offers a capped patient-pay program for those without full coverage.

How accurate is Genomind testing?

The genotyping is performed in a CLIA-certified laboratory and is highly accurate at the genetic level. Clinical judgment matters in interpretation: a gene variant points to a probability, not a guarantee. Genomind's recommendations follow peer-reviewed literature and CPIC guidelines and are intended to support, not replace, your psychiatrist's decision-making.

What is the difference between Genomind and GeneSight?

Both are buccal-swab pharmacogenomic tests that score psychiatric medications based on your genes. Genomind tests roughly 24 genes covering 130+ medications across psychiatry, neurology, and other specialties. GeneSight tests roughly 14 genes covering 60+ primarily psychiatric medications. Genomind reports use a green / yellow / red color system; GeneSight uses three columns. Both are credible, evidence-based options.

How long does Genomind testing take?

Sample collection takes about two minutes in office. Results are typically available within three to five business days after the lab receives the sample. We then schedule a follow-up appointment to review the results with you in detail.

What medications does Genomind test for?

The Genomind Professional PGx panel covers more than 130 medications, including most SSRIs, SNRIs, tricyclic antidepressants, atypical antidepressants, anti-anxiety medications, mood stabilizers, antipsychotics, ADHD medications, sleep medications, and selected medications used in pain management, neurology, and cardiology.

Can pharmacogenomic testing predict if an antidepressant will work?

No test can guarantee a specific antidepressant will work for a specific person. Pharmacogenomic testing improves the odds by identifying medications more likely to be tolerated and effective based on your genetics. Real-world response still depends on accurate diagnosis, appropriate dose, consistent use, and ongoing follow-up.

Take the Next Step

If you want a more informed approach to your treatment, ask about Genomind gene testing in Ashburn, VA. We integrate results directly into psychiatric medication management guided by your results, so the data shapes the plan you leave with.

Gonzales-Vigilar Psychiatric Services is at 44031 Pipeline Plaza, Suite 200, Ashburn, VA. Call 571-291-2449 to schedule.

This article is for educational purposes and is not a substitute for medical advice. If you are in crisis, call or text the 988 Suicide and Crisis Lifeline.